Description of pharmaceutical activities and the use of radiopharmaceuticals in a hospital radiopharmacy of the teaching hospital in southern Brazil
DOI:
https://doi.org/10.30968/jhphs.2025.163.1221Abstract
Objective: To present the pharmacist´s activities developed in a nuclear medicine service of university hospital. Method: Retrospective descriptive study based on data from 2015 to 2022 and organized in productivity, logistics, and patient safety. Results: As for productivity, on average, 498 doses/month manipulations, 102 99mTc-radiopharmaceuticals/month and 3.4 oral capsules/month were administered. Of the quality controls, 96.7% of the 99mTc-eluates were approved and 93.5% of the 99mTc-radiopharmaceuticals were approved for administration. Of the ready-to-use radiopharmaceuticals for diagnostic purposes, 18F-FDG corresponded to 71.2% of the manipulations. As for logistics, the management of lyophilized reagents provided a reduction in losses due to expirations from 40% to 8.6%. Regarding patient safety, 03 cases of adverse drug reactions were identified after the administration of radiopharmaceuticals dextran (99mTc), sodium iodide (131I) and sestamibi (99mTc), being classified as possible and probable, and 35 medications errors involving radiopharmaceuticals, being 28.6% related to sestamibi (99mTc). Conclusion: The pharmacist, with knowledge and expertise in drugs, can collaborate with safety and quality issues in internal processes regarding the use of radiopharmaceuticals.
Downloads
References
World Health Organization. Radiopharmaceutical products. In: Quality assurance of pharmaceuticals: A compendium of guidelines and related materials. Geneva:WHO;2007.
Ziessman HA, O´Malley JP, Thrall JH, et al. Medicina Nuclear. Rio de Janeiro: Elsevier;2015.
Saha, GB. Fundamentals of Nuclear Pharmacy. Cleveland: Springer; 2018.
International Atomic Energy Agency (IAEA). Operational guidance on hospital radiopharmacy: a safe and effective approach. Vienna:IAEA;2008.
Kasalak Ö, Yakar D, Dierckx RAJO, et al. Patient safety in nuclear medicine: identification of key strategic areas for vigilance and improvement. Nucl Med Commun. 2020;41(11):1111-1116. doi:10.1097/MNM.0000000000001262
Araújo EB, Lavinas T, Colturato MT, et al. Garantia da qualidade aplicada à produção de radiofármacos. Braz J Pharm Sci. 2008;44(1):1-12. doi:10.1590/S1516-93322008000100002
Santos-Oliveira R, Bencke MR, Donato R, et al. Radiofarmacos, Radiofarmácia e Medicina Nuclear. Infarma. 2009;21(9/10):3-6.
Brasil MP, de Barros MP, Antunes LJ, et al. Hospital nuclear pharmacy survey: preliminary aspects in Brazil. J Young Pharm. 2012;4(4):279-281. doi:10.4103/0975-1483.104373
Oliveira R, Santos D, Ferreira D, et al. Preparações radiofarmacêuticas e suas aplicações. Rev Bras Cienc Farm. 2006; 42(2):151-165. doi:10.1590/S1516-93322006000200002
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi: 10.1038/clpt.1981.154
Pereira de Lima SH, Cirilo AM, Silva TV, et al. A inserção do farmacêutico na radiofarmácia: com ênfase no iodeto de sódio para fins de diagnóstico e tratamento de disfunções na tireoide. Brazilian Journal of Development. 2022;8(1):6482-6500. doi:10.34117/bjdv8n1-439
Pozzo L, Oliveira ML, Menezes MO, et al. Nuclear Medicine in Brazilian Health System. A Medicina Nuclear no Sistema Único de Saúde. Cien Saude Colet. 2025;30(1):e04962023. doi:10.1590/1413-81232025301.04962023
Soares Júnior J, Fonseca RP, Cerci JJ, et al. Lista de recomendações do Exame PET/CT com 18F-FDG em Oncologia: consenso entre a Sociedade Brasileira de Cancerologia e a Sociedade Brasileira de Biologia, Medicina Nuclear e Imagem Molecular. Radiol Bras. 2010;43(4):255-259. doi:10.1590/S0100-39842010000400010
Bertoldi K, Erig LSS, Glaeser A, et al. Caracterização de exames PET-CT realizados no serviço de medicina nuclear em um hospital no sul do Brasil. Alasbimn Journal. 2022;(18-jan):1-5.
Marques FLN, Okamoto MRY, Buchpiguel CA. Alguns aspectos sobre geradores e radiofármacos de tecnécio-99m e seus controles de qualidade. Radiol Bras. 2001;34(4):233-239. doi:10.1590/S0100-39842001000400011
Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010;40(4):220-241. doi:10.1053/j.semnuclmed.2010.02.004
Pérez-Iruela JA, Pastor-Fructuoso P, Gracia-Rodríguez CD, et al. Adverse reactions to radiopharmaceuticals. Farm Hosp. 2021;45(3):142-149. doi: 10.7399/fh.11669
Santos-Oliveira R, Machado M. Pitfalls with radiopharmaceuticals. Am J Med Sci. 2011;342(1):50-53. doi:10.1097/MAJ.0b013e318216ee86
Schreuder N, Koopman D, Jager PL, et al. Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. Semin Nucl Med. 2019;49(5):382-410. doi:10.1053/j.semnuclmed.2019.06.006
Silberstein EB. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011. J Nucl Med. 2014;55(8):1308-1310. doi: 10.2967/jnumed.114.138057
Schreuder N, Jacobs NA, Jager PL, et al. Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. Drug Saf. 2021;44(2):211-222. doi:10.1007/s40264-020-01006-2
Ramim JE, Cardoso MAS, Oliveira GLC, et al. Healthrelated quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public cancer hospital in Brazil. Support Care Cancer. 2020;28(8):3771-3779. doi:10.1007/s00520-019-05225-x
Larcos G, Prgomet M, Georgiou A, et al. A work observation study of nuclear medicine technologists: interruptions, resilience and implications for patient safety. BMJ Qual Saf. 2017;26(6):466-474. doi:10.1136/bmjqs-2016-005846
Hedlund N, Beer I, Hoppe-Tichy T, et al. Systematic evidence review of rates and burden of harm of intravenous admixture drug preparation errors in healthcare settings. BMJ Open. 2017;7(12):e015912. doi:10.1136/bmjopen-2017-015912
Kearney N, Denham G. Recommendations for Nuclear Medicine Technologists Drawn from an Analysis of Errors Reported in Australian Radiation Incident Registers. J Nucl Med Technol. 2016;44(4):243-247. doi:10.2967/jnmt.116.178517
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to JHPHS : (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to JHPHS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
